Stocks · News reference
Rapport Therapeutics Director Steven M. Paul purchased 35,714 shares of the company's common stock for approximately $974,278.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Rapport Therapeutics announced the pricing of its previously proposed public offerings, totaling approximately $175 million in common stock and $150 million in convertible senior notes.
Rapport Therapeutics has commenced separate underwritten public offerings of $200 million in common stock and $150 million in convertible senior notes due 2032.
Goldman Sachs analyst Salveen Richter maintained a 'Buy' rating on Rapport Therapeutics and increased the price target from $62 to $68.